151 related articles for article (PubMed ID: 19916175)
1. G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence.
Lodato F; Azzaroli F; Tamè MR; Di Girolamo M; Buonfiglioli F; Mazzella N; Cecinato P; Roda E; Mazzella G
World J Gastroenterol; 2009 Nov; 15(43):5449-54. PubMed ID: 19916175
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
Koirala J; Gandotra SD; Rao S; Sangwan G; Mushtaq A; Htwe TH; Adamski A; Blessman D; Khardori NM
J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
[TBL] [Abstract][Full Text] [Related]
3. Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
Tajuddin T; Ryan EJ; Norris S; Hegarty JE; O'Farrelly C
J Gastroenterol Hepatol; 2010 Dec; 25(12):1883-90. PubMed ID: 21092001
[TBL] [Abstract][Full Text] [Related]
4. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts.
Durante-Mangoni E; Iardino P; Utili R; Adinolfi LE; Ruggiero G
Antivir Ther; 2006; 11(5):637-40. PubMed ID: 16964833
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
Koskinas J; Zacharakis G; Sidiropoulos J; Elefsiniotis J; Savvas S; Kotsiou S; Kountouras D; Schina M; Kostopoulos P; Archimandritis A
J Med Virol; 2009 May; 81(5):848-52. PubMed ID: 19319942
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.
Tandon P; Doucette K; Fassbender K; Vandermeer B; Durec T; Dryden DM
J Viral Hepat; 2011 Jul; 18(7):e381-93. PubMed ID: 21692951
[TBL] [Abstract][Full Text] [Related]
7. Lenograstim in the treatment of severe neutropenia in patients treated with Peg-IFN and ribavirin: the experience of a single hepatology unit.
Tarantino L; De Rosa A; Tambaro O; Ripa C; Celiento M; Schiano A
Infez Med; 2009 Mar; 17(1):20-3. PubMed ID: 19359820
[TBL] [Abstract][Full Text] [Related]
8. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
[TBL] [Abstract][Full Text] [Related]
9. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
Mac Nicholas R; Norris S
Aliment Pharmacol Ther; 2010 May; 31(9):929-37. PubMed ID: 20175767
[TBL] [Abstract][Full Text] [Related]
10. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
Coilly A; Dumortier J; Botta-Fridlund D; Latournerie M; Leroy V; Pageaux GP; Agostini H; Giostra E; Moreno C; Roche B; Antonini TM; Guillaud O; Lebray P; Radenne S; Saouli AC; Calmus Y; Alric L; Debette-Gratien M; De Ledinghen V; Durand F; Duvoux C; Samuel D; Duclos-Vallée JC
PLoS One; 2015; 10(9):e0138091. PubMed ID: 26394142
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
12. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
Gopal DV; Rabkin JM; Berk BS; Corless CL; Chou S; Olyaei A; Orloff SL; Rosen HR
Liver Transpl; 2001 Mar; 7(3):181-90. PubMed ID: 11244158
[TBL] [Abstract][Full Text] [Related]
13. Reduction in neutrophil count during hepatitis C treatment: drug toxicity or predictor of good response?
Alvarez-Uria G; Day JN; Nasir AJ; Russell SK; Vilar FJ
Dig Dis Sci; 2010 Jul; 55(7):2058-62. PubMed ID: 19757045
[TBL] [Abstract][Full Text] [Related]
14. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
[TBL] [Abstract][Full Text] [Related]
15. Multiple, repeated filgrastim treatment cycles to recover severe, recurring pegylated interferon-related neutropenia.
Manfredi R; Sabbatani S
Hepatogastroenterology; 2007 Sep; 54(78):4 page preceeding table content. PubMed ID: 18019674
[No Abstract] [Full Text] [Related]
16. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
Liu YL; Du XF; Chen XY; Ma LN; Guo DD; Lu JF; Cao ZH; Zhang YH
Scand J Infect Dis; 2013 Dec; 45(12):939-43. PubMed ID: 24090457
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response.
Jiménez-Pérez M; Sáez-Gómez AB; Pérez-Daga JA; Lozano-Rey JM; de la Cruz-Lombardo J; Rodrigo-López JM
Transplant Proc; 2010 Mar; 42(2):666-8. PubMed ID: 20304219
[TBL] [Abstract][Full Text] [Related]
19. Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C.
Yada M; Masumoto A; Yamashita N; Motomura K; Koyanagi T; Sakamoto S
World J Gastroenterol; 2010 Mar; 16(12):1506-11. PubMed ID: 20333792
[TBL] [Abstract][Full Text] [Related]
20. A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.
Saleh MI; Hindi NN
Naunyn Schmiedebergs Arch Pharmacol; 2018 Sep; 391(9):953-963. PubMed ID: 29872876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
